Black and Indigenous patients are under-represented in recent randomized controlled trials for systemic lupus erythematosusTrial Data Shows Diverse Patients Underrepresented in Lupus Research

Autoimmunity reviews Published August 3, 2026 Study authors: Turk Matthew A, Hausman Jordan, Pope Janet E PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note significant under-representation of Black and Indigenous patients in recent systemic lupus erythematosus trials.

This meta-analysis synthesized data from 63 randomized controlled trials conducted between 2014 and 2024 to evaluate the demographic composition of participants in pharmaceutical interventions for systemic lupus erythematosus (SLE). The analysis focused on racial, ethnic, and gender distributions to identify representation gaps in current clinical research.

The findings indicate a heavy skew toward female participants, who comprised 91% of the study population. Regarding ethnicity, White participants accounted for 61%, while Hispanic/Latino participants were represented at 37%. Significant under-representation was noted among minority groups: Black participants accounted for 14%, Asian participants for 14%, and Indigenous participants (including Native American) for 8%. Pacific Islander representation was less than 1%.

A primary limitation noted by the authors is the inconsistent reporting of race and ethnicity across different trials, which limits the precise interpretation of Hispanic/Latino representation. These findings highlight a significant gap in diversity within SLE clinical trials, particularly for Black and Indigenous populations. This data suggests that current evidence bases may not fully reflect the experiences or treatment responses of diverse patient populations with systemic lupus erythematosus.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the demographic diversity of trial participants in systemic lupus erythematosus. While previous coverage identified potential biomarkers like GDF15 and various signaling targets such as FGF/FGFR, this study highlights that the clinical evidence base may lack sufficient representation for Black (14%) and Indigenous (8%) patients. It complements existing knowledge on SLE by highlighting the demographic limitations of current pharmaceutical trial data.

A review of 63 different studies conducted between 2014 and 2024 looked at the diversity of people participating in drug trials for systemic lupus erythematosus (SLE). The goal was to see how well the research represented different genders and ethnicities.

The results showed that women made up 91% of the participants. While Hispanic or Latino patients were included at a rate of 37%, other groups were much less represented. Specifically, Black participants made up 14% of the trials, Asian participants made up 14%, and Indigenous participants made up 8%. Pacific Islander representation was less than 1%.

Because many minority groups are not well-represented in these studies, it can be harder to know how certain treatments work for everyone. This information is important because diverse data helps doctors understand how medications affect different types of patients. These findings highlight a need for more inclusive research to ensure all patients receive the best care possible.

What this means for you:

Many ethnic and racial minority groups are under-represented in recent clinical trials for lupus treatment.

Common questions

Who is represented in current lupus drug trials?

The study found that women make up 91% of participants in these trials. While Hispanic or Latino patients are included at a rate of 37%, other groups like Black and Asian participants each make up only 14% of the total population studied between 2014 and 2024.

Are minority groups well-represented in lupus research?

The data shows that many minority groups are under-represented. For example, Indigenous participants make up only 8% of the trials, and Pacific Islander participation is less than 1%. This means there is less data available for these specific groups.

Why does diversity in clinical trials matter?

When diverse groups are not included in enough studies, it can be harder for doctors to know how a treatment affects everyone. More inclusive research helps ensure that medications are tested and understood for all patients with systemic lupus erythematosus.

Study Details

Study typeMeta analysis

Sample sizen = 50

EvidenceLevel 1

PublishedAug 2026

PMID42190855

View Original Abstract ↓

BACKGROUND: With numerous emerging treatments for systemic lupus erythematosus (SLE), it is imperative that clinical trials include diverse populations reflective of those with SLE, especially active disease. Epidemiological data from North America and Europe indicate that the prevalence of SLE is disproportionately higher among Black populations compared to White populations, relative to their distribution in the general population. The objectives of this study were to examine the racial composition of randomized controlled trials (RCTs) in SLE from 2014 to 2024, assessing whether these trials accurately represent the diversity of SLE populations. METHODS: A systematic review of the literature was conducted using EMBASE, PUBMED, Web of Science, and Cochrane CENTRAL from Jan 1, 2014 - May 14, 2024. RCTs of pharmaceutical interventions in SLE patients were included. Studies were excluded if they had less than 50 participants, were not in English, or did not report on race/ethnicity. Revman 5.4 and SPSS were used for statistical analysis. RESULTS: Of 2505 studies identified, 63 were included. The pooled proportion of women was 91%. Among studies reporting these categories, White participants represented 61% of trial participants, Black participants 14%, Asian participants 14%, and Indigenous (including Native American) participants 8%, whereas fewer than 1% were Pacific Islanders. Hispanic/Latino ethnicity, which was variably reported across studies and may overlap with racial categories, was reported in 37% of participants. CONCLUSION: Racial and ethnic minority groups appear under-represented in recent SLE RCTs, particularly Black participants. Interpretation of Hispanic/Latino representation is limited by inconsistent reporting of race and ethnicity across trials. Greater effort is needed to ensure that SLE research trials are generalizable to patients and equitable with respect to patient diversity.

Black and Indigenous patients are under-represented in recent randomized controlled trials for systemic lupus erythematosusTrial Data Shows Diverse Patients Underrepresented in Lupus Research

How this fits prior evidence

Common questions

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Black and Indigenous patients are under-represented in recent randomized controlled trials for systemic lupus erythematosusTrial Data Shows Diverse Patients Underrepresented in Lupus Research

How this fits prior evidence

Common questions

More on Systemic Lupus Erythematosus

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties